Protara Therapeutics – Consensus Indicates Potential 117.4% Upside

Broker Ratings

Protara Therapeutics found using ticker (TARA) now have 4 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 50 and 37 and has a mean target at 45. Now with the previous closing price of 20.7 this is indicating there is a potential upside of 117.4%. The 50 day MA is 20.22 and the 200 moving average now moves to 20.96. The market cap for the company is $202m. You can visit the company’s website by visiting:

Protara Therapeutics, a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics and changed its name to Protara Therapeutics in May 2020. Protara Therapeutics is based in New York, New York.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index